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Abstract 
Background.  Doxorubicin (DOX) is a widely used and effective anti-cancer 
therapeutic.  DOX treatment is associated with both acute and late onset cardiotoxicity, 
limiting its overall efficacy.  Here, the impact of cardiomyocyte cell cycle activation was 
examined in a juvenile model featuring aspects of acute and late onset DOX 
cardiotoxicity. 
Methods and Results.  Two-week old MHC-cycD2 transgenic mice (which express 
cyclin D2 in postnatal cardiomyocytes and exhibit sustained cardiomyocyte cell cycle 
activity; D2 mice) and their wild type (WT) littermates received weekly DOX injections 
for 5 weeks (25 mg/kg cumulative dose).   One week after the last DOX treatment 
(acute stage), cardiac function was suppressed in both groups. Acute DOX 
cardiotoxicity in D2 and WT mice was associated with similar increases in the levels of 
cardiomyocyte apoptosis and Ku70 / Ku80 expression (markers of DNA damage and 
oxidative stress), as well as similar reductions in hypertrophic cardiomyocyte growth. 
Cardiac dysfunction persisted in WT mice for 13 weeks following the last DOX treatment 
(late stage), and was accompanied by increased levels of cardiomyocyte apoptosis, Ku 
expression and myocardial fibrosis.  In contrast, D2 mice exhibited a progressive 
recovery in cardiac function, which was indistinguishable from saline-treated animals by 
9 weeks following the last DOX treatment.  Improved cardiac function was accompanied 
by reductions in the levels of late stage cardiomyocyte apoptosis, Ku expression and 
myocardial fibrosis.      
Conclusions. These data suggest that cardiomyocyte cell cycle activity can promote 
recovery of cardiac function and preserve cardiac structure following DOX treatment. 
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Introduction 
Anthracyclines such as doxorubicin (DOX) are highly effective anti-cancer 
therapeutics.  These agents are also highly cardiotoxic. Acute cardiac responses to 
anthracycline treatment are transient and usually occur within several days of treatment. 
Symptoms include hypotension, tachycardia, arrhythmia and reduction of ventricular 
function.1-4 Patients can also present with recalcitrant heart failure months or years after 
anthracycline treatment is terminated, the severity of which is directly related to 
cumulative drug exposure.  It has been estimated that the risk of developing 
cardiomyopathy is 4% when the dose of DOX is 500–550 mg/m2, 18% when the dose is 
551–600 mg/m2 and 36% when the dose exceeds 600 mg/m2.2, 5 Pediatric patients are 
particularly sensitive to anthracycline-induced heart failure.6, 7   
Anthracycline treatment has many adverse consequences for cardiomyocytes. 
For example, treatment results in a reduction in protein synthesis, inhibition of myogenic 
transcriptional programs and induction of myofiber degeneration,reviewed in 8, 9 which 
collectively are likely to contribute to the transient anthracycline-induced cardiomyocyte 
atrophy and suppressed cardiac function observed during acute treatment.  Treatment 
also results in increased levels of reactive oxygen species, increased levels of DNA 
damage and reduced electron transport chain transcriptome activity.reviewed in 10-13 These 
changes collectively are likely to contribute to the high rates of cardiomyocyte apoptosis 
observed following anthracycline treatment in vitro and in vivo. Although many 
molecular pathways have been implicated in anthracycline-induced cardiotoxicity, the 
precise mechanisms which give rise to acute vs. late onset disease remain elusive.   
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Many forms of cardiac disease are associated with a concomitant loss of 
cardiomyocytes.  This has led to the relatively simple notion that increasing 
cardiomyocyte renewal rates could stabilize, or even reverse, the progression of heart 
failure.  Accordingly, we have examined the impact of enhanced cardiomyocyte renewal 
rates in a juvenile model of DOX-induced heart failure which exhibits aspects of acute 
and late stage cardiotoxicity.14  We utilized MHC-cycD2 mice (D2 mice), which express 
cyclin D2 (a key cell cycle regulator) under the control of the cardiomyocyte-specific 
myosin heavy chain promoter.  These animals exhibit sustained increases in postnatal 
cardiomyocyte S-phase activity, phosphorylated histone H3 expression, and 
cardiomyocyte division (the latter evidenced by increased cell numbers in dispersed cell 
preparations) as compared to their wild type (WT) littermates.15, 16  Interestingly, 
cardiomyocyte nucleation patterns are normal in these mice.15 Previous studies have 
shown that enhanced cardiomyocyte renewal rates in D2 mice are associated with  
progressive structural and functional recovery following myocardial infarction,15, 17, 18 
cytokine-induced atrial fibrosis,19 and chronic pressure overload.16  We show here that 
the enhanced level of cardiomyocyte renewal in D2 mice is associated with progressive 
recovery from anthracycline-induced heart failure. 
Methods 
Please see the Supplemental Data Section for a more detailed description of the 
methods employed in this study. 
Mice.  This study utilized mice generated by intercrossing MHC-cycD215 and MHC-
nLAC20 transgenic animals. The number of mice used to generate each data set are 
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indicated in the Supplemental Data Figures. All animal protocols were approved by the 
Indiana University School of Medicine Institutional Animal Care and Use Committee. 
Echocardiography. Mice were anesthetized with 1.5% isoflurane and two-dimensional 
images were obtained using a VisualSonics Vevo 770 instrument as described.21  
Cardiomyocyte DNA synthesis assay.  Cardiomyocyte DNA synthesis was monitored 
via tritiated thymidine incorporation  as described.20, 22   
Statistical analysis. All values are presented as mean ± SEM. Statistical significance 
was determined using Student’s t-test for comparison of two groups, and Two-Way 
ANOVA with Bonferroni correction for comparison between 3 groups or more. p<0.05 
was considered significant.  
Results 
D2 mice exhibit a progressive improvement in cardiac function following DOX-
induced cardiotoxicity 
 To determine the impact of cardiomyocyte cell cycle activity following 
anthracycline treatment, two week old WT mice and their D2 transgenic littermates were 
enrolled in a long-term DOX cardiotoxicity study (some of the mice also carried the 
MHC-nLAC20 reporter transgene). The mice received 5 weekly injections of saline or 5 
weekly injections of DOX (5 mg/kg/injection, 25 mg/kg cumulative dose).  Cardiac 
function was assessed via ultrasound prior to the first injection (i.e., at two weeks of 
age), one week after the last injection (i.e., 7 weeks of age) and subsequently at 15 and 
19 weeks of age.  Cardiac function was similar in all groups prior to the initial injection 
(Figure 1A).  Cardiac function remained stable in the saline-treated WT and D2 mice 
over the course of the study.  DOX-treated WT mice exhibited decreased cardiac 
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function when examined one week after the last treatment (designated the “acute 
stage”), and cardiac function remained suppressed up to 19 weeks of age (designated 
the “late stage”), the last time point examined. DOX-treated D2 mice also exhibited 
decreased cardiac function when examined at the acute stage, albeit with a tendency 
towards being less severe than what was seen in DOX-treated WT mice.  The DOX-
treated D2 mice exhibited a progressive restoration of cardiac function, which was 
normal by 15 weeks of age.  Figure 1B shows representative short-axis 
echocardiograms of saline- and DOX-treated mice (see also Supplemental Tables 1 
and 2).  
 Western blot analyses were performed to confirm expression of the MHC-cycD2 
transgene. As expected, mice carrying the transgene exhibited cyclin D2 expression in 
both the acute and late stages, and expression was not altered by DOX treatment 
(Figure 2A). Expression of endogenous CDK4 was also elevated in D2 mice as 
compared to WT mice, in agreement with previous observations.15  To monitor 
cardiomyocyte DNA synthesis, the mice received an injection of tritiated thymidine (3H-
Thy) four hours prior to sacrifice. After harvest, the hearts were sectioned, and the 
sections were reacted with the chromogenic β-galactosidase substrate 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (X-GAL, which is used to identify cardiomyocyte 
nuclei in mice carrying the MHC-nLAC reporter) and processed for autoradiography. S-
phase cardiomyocyte nuclei were readily identified by the presence of silver grains 
overlaying blue X-GAL reaction product (Figure 2B). In agreement with previous 
studies,15, 16, 18 saline-treated D2 mice had markedly elevated levels of cardiomyocyte S-
phase activity as compared to saline-treated WT mice (Figure 2C).  DOX treatment 
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy273/5181163 by IU
PU
I U
niversity Library user on 03 D
ecem
ber 2018
  CVR-2018-783-R1; Page 8 
 
resulted in a 5-fold decrease in S-phase activity in the D2 mice when assessed in the 
acute stage.   Surprisingly, reduced levels of cardiomyocyte S-phase activity persisted 
in late stage D2 mice.   
D2 mice exhibit reduced late stage cardiomyocyte apoptosis 
 Activated caspase-3 immune reactivity was used to quantitate cardiomyocyte 
apoptosis; since activated caspase-3 is localized in the cytoplasm, early-stage apoptotic 
cardiomyocytes are identified based on the presence of cytoplasmic activated caspase-
3 immune reactivity in rod-shaped cells (Figure 3A).23  DOX treatment induced 
cardiomyocyte apoptosis in WT juvenile mice during the acute stage (Figure 3B), and 
late stage animals exhibited even higher levels of apoptosis despite the termination of 
treatment (in good agreement with earlier studies).14, 24  DOX-treated D2 mice exhibited 
similar levels of acute stage cardiomyocyte apoptosis as was observed for WT mice.  In 
contrast to the WT mice, the level of cardiomyocyte apoptosis did not further increase in 
late stage DOX-treated D2 mice.  Interestingly, the level of cardiomyocyte tritiated 
thymidine incorporation/mm2 was greater than the level of cardiomyocyte activated 
caspase 3 immune reactivity/mm2 in DOX-treated D2 mice during both the acute and 
late stages; in contrast, the level of tritiated thymidine incorporation was lower than the 
level of activated caspase 3 in DOX-treated WT mice (Figure 3C).  
Ku (a heterodimer protein complex comprising Ku70 and Ku80) is induced in 
response to DNA damage,25 and Ku70 is also thought to function as a transcriptional 
co-factor in response to oxidative stress.26, 27  DOX treatment induced Ku expression in 
WT juvenile mice during the acute stage (Figure 3D), and late stage animals exhibited 
even higher levels of expression (in good agreement with earlier studies).24   DOX 
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treatment induced Ku expression in acute stage D2 mice to a similar degree as was 
seen in WT mice.  Interestingly, Ku levels were reduced in late stage D2 mice.  
Myocardial remodeling following DOX treatment 
 Acute DOX treatment is known to induce cardiomyocyte atrophy in adult hearts28 
and to reduce hypertrophic cardiomyocyte growth in juvenile hearts.14 Previous studies 
have shown that minimal fiber diameter (MFD) measurements in histologic sections 
provide a reliable index of cardiomyocyte hypertrophy or atrophy.29  MFD was similarly 
reduced in DOX-treated WT and D2 mice during the acute stage, and was normalized in 
both groups during the late stage (Figure 4A). Finally, Sirius red/fast green staining was 
used to quantitate myocardial collagen deposition, which is indicative of fibrosis. No 
overt difference in myocardial Sirius red content was observed in saline- vs. DOX-
treated mice during the acute stage (Figure 4B). DOX-treated WT mice exhibited 
increased levels of myocardial Sirius red staining during the late stage, indicative of 
increased fibrosis.  In contrast, there was no increase in myocardial Sirius red staining 
in late stage D2 mice.  Figure 4C shows representative images from DOX-treated WT 
and D2 hearts. Interestingly, cyclin D2 expression had no impact on vascular density 
(Supplemental Figures 7 and 8). 
Discussion  
We have previously shown15, 16 that D2 mice exhibit sustained cyclin D2 
expression for up to 12 months of age (the latest time point tested).  Transgene 
exppression is accompanied with cardiomyocyte cell cycle activity, as evidenced by the 
presence of elevated levels of cardiomyocyte S-phase activity, elevated levels of 
cardiomyocyte phosphorylated histone H3 immune reactivity, and increased 
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cardiomyocyte numbers in postnatal hearts. Transgene expression has no detrimental 
impact on cardiac function in this model. The data presented here demonstrate that the 
presence of sustained cardiomyocyte cell cycle activity in D2 mice is associated with a 
progressive recovery in cardiac function in a juvenile model of anthracycline-induced 
cardiotoxicity.  In contrast, cardiac function remained repressed in DOX-treated WT 
mice.  The observed effects in the D2 mice must cell autologous, as the transgene is 
only expressed in cardiomyocytes (Supplemental Figure 9).15 
The similar impact on the levels of cardiomyocyte apoptosis, Ku induction and 
inhibition of developmental hypertrophic growth indicate that cardiomyocytes from WT 
and D2 DOX-treated mice were subjected to a similar degree of injury at the cellular 
level during the acute stage. In WT mice, the level of S-phase activity was lower than 
the level of activated caspase 3 immune reactivity in the acute stage (3-fold) and much 
lower in the late stage (25-fold), indicating a progressive net loss of cardiomyocytes. 
The increase in Ku expression observed in the late stage WT mice suggests a model 
wherein the inability to replace cardiomyocyte loss in response to DOX treatment results 
in increased myocardial stress, which would in turn contribute to increased levels of 
cardiomyocyte apoptosis and ultimately myocardial fibrosis.  
In contrast, and despite a sustained reduction in tritiated thymidine incorporation, 
the level of cardiomyocyte S-phase activity (which we have previously shown correlates 
to renewal in the D2 model, see above) is more than 5-fold greater than the level of 
cardiomyocyte apoptosis in DOX-treated D2 mice in both the acute and late stages. 
This suggests that the rate of cardiomyocyte replacement is greater than the drop-out 
rate (even when one takes into consideration the likely differences in the duration of S-
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phase vs. activated caspase-3 immune positivity). The presence of elevated levels of 
cardiomyocyte cell cycle activity was associated with improved cardiac function and no 
further induction of cardiac stress (as evidenced by the normalization of Ku expression 
and the absence of myocardial fibrosis in late stage DOX-treated D2 mice). Thus, the 
level of cardiomyocyte apoptosis would not be expected to increase in late stage D2 
mice (which is what was observed). The presence of similar levels of cardiomyocyte 
apoptosis in acute and late stage D2 mice (as opposed to the absence of late stage 
apoptosis) is consistent with a recent study suggesting that DOX induces a permanent 
change in the mitochondrial gene transcriptome which contributes to sustained 
cardiomyocyte dysfunction and apoptosis after drug withdrawal.10    
Although DOX treatment resulted in a similar degree of cardiomyocyte injury in 
WT and D2 mice at the cellular level, EF was greater in DOX-treated D2 vs. DOX-
treated WT mice in the acute stage (although the difference was not statistically 
different).  It should be noted that postnatal D2 mice have a greater cardiomyocyte 
content than their non-transgenic littermates.16 Thus, despite a similar impact of DOX 
treatment at the cellular level, the presence of more cardiomyocytes could readily 
explain the better cardiac function observed at the organ level in D2 vs. WT mice during 
the acute stage.  In contrast, the progressive restoration of normal cardiac function in 
late stage DOX-treated D2 mice likely results from increased levels of cardiomyocyte 
renewal and a concomitant decrease in adverse remodeling. 
While a reduction in cardiomyocyte S-phase is to be expected in DOX-treated D2 
mice during the acute stage due to the anti-proliferative activity of anthracyclines, it is 
not clear why S-phase levels remain repressed during the late stage, particularly as 
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DOX treatment had no impact on expression of the transgene or endogenous CDK4. It 
is possible that the pool of proliferating cardiomyocytes in D2 mice (that is, the fraction 
of cyclin D2-expressing cardiomyocytes able to enter the cell cycle) is rather small. If so, 
5 successive rounds of DOX injection would be expected to markedly deplete the pool, 
resulting in a permanent reduction in the thymidine labeling index. Alternatively, it is 
possible that there is a labile cardiomyogenic stem cell population which is 
progressively eliminated by DOX treatment over time. However, recent results using a 
lineage trace system demonstrated that DOX treatment actually enhances 
cardiomyogenic activity in putative c-kit progenitor cells,30 thus a permanent reduction in 
transgene-induced cardiomyocyte S-phase activity would not be anticipated (particularly 
since the MHC-cycD2 transgene would not be expected to be expressed in a progenitor 
cell which has not yet adopted a cardiac phenotype). 
 In summary, the data here support the notion that increased rates of 
cardiomyocyte renewal can lead to normalization of cardiac function in a juvenile model 
of DOX-induced cardiotoxicity. Such an approach might be viable to ameliorate, or 
reverse, late onset cardiomyopathy sometimes encountered in cancer patients treated 
with anthracyclines. 
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Figure Legends 
Figure 1.  Cardiac function in saline- and DOX-treated WT and D2 mice. (A) Fractional 
Shortening (FS) in saline- and DOX-treated WT and D2 mice at 2, 7, 15 and 19 weeks 
of age.  Vertical arrows indicate the age at saline or DOX injection. “*”: p < 0.05 vs. WT-
Saline; “†”: p<0.05 vs. D2-Saline; “‡”: p < 0.001 vs. D2-DOX; Two-Way ANOVA with 
Bonferroni correction). See Supplemental Figure 1 for a scatter plot of the FS values for 
the individual animals studied.  (B) Representative short axis echocardiograms from 
saline- and DOX-treated WT and D2 mice during the acute and late stages. 
Figure 2. Transgene expression and cardiomyocyte DNA synthesis in acute stage and 
late stage mice.  (A) Western blot analysis of cyclin D2 and CDK4 expression in saline- 
and DOX-treated WT and D2 mice during the acute and late stages. (B)  Image of a 
section from a D2 mouse heart harvested 4 hours after 3H-Thy injection (the mouse also 
carried the MHC-nLAC reporter transgene). The section was reacted with X-GAL to 
identify cardiomyocyte nuclei and processed for autoradiography to identify 3H-Thy 
incorporation. The presence of black silver grains over blue X-GAL reaction product is 
indicative of an S-phase cardiomyocyte nucleus (see arrows; bar = 10 microns).  (C) 
Quantitation of cardiomyocyte 3H-Thy labeling in saline- and DOX-treated WT and D2 
mice during the acute and late stages (Two-Way ANOVA with Bonferroni correction). 
See Supplemental Figure 2 for a scatter plot of the 3H-Thy labeling indices for the 
individual animals studied. 
Figure 3. Cardiomyocyte apoptosis and myocardial stress in acute and late stage mice. 
(A) Representative image of an activated caspase-3 immune reactive cardiomyocyte 
from a DOX-treated mouse.  Bar = 25 microns.  (B) Quantitation of activated caspase-3 
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immune reactive cardiomyocytes (CSP3+ CM) per mm2 in hearts from saline- and DOX-
treated WT and D2 mice during the acute and late stages (Two-Way ANOVA with 
Bonferroni correction). See Supplemental Figure 3 for a scatter plot of the 
cardiomyocyte activated caspase-3 values for the individual animals studied. (C) Levels 
of tritiated thymidine-positive cardiomyocytes and activated caspase-3-positive 
cardiomyocytes per mm2 myocardial tissue from DOX-treated WT and D2 mice during 
the acute and late stages (Two-Way ANOVA with Bonferroni correction). (D) Western 
blot analysis of Ku70 and Ku80 expression in hearts from saline- and DOX-treated WT 
and D2 mice during the acute and late stages.  See Supplemental Figure 4 for 
quantitation of the Ku70 and Ku80 signals.   
Figure 4. Myocardial atrophy and fibrosis in acute and late stage mice.  (A) Quantitation 
of cardiomyocyte MFD in hearts from saline- and DOX-treated WT and D2 mice during 
the acute and late stages. See Supplemental Figure 5 for a scatter plot of the average 
MFDs for the individual animals studied.  (B) Quantitation of Sirius red myocardial 
content in hearts from saline- and DOX-treated WT and D2 mice during the acute and 
late stages (Two-Way ANOVA with Bonferroni correction). See Supplemental Figure 6 
for a scatter plot of the myocardial Sirius red content for the individual animals studied. 
(C) Representative images of Sirius red/fast green-stained heart sections prepared from 
saline- and DOX-treated late stage WT and D2 mice (bar = 50 microns). 
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Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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